drugset / Trial / NCT00199407

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

NCT00199407

Phase 3 Completed 230 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

Timeline

Start
2004-06
Primary completion
2005-11
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 20 mg Oral

Indications